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Cytokines, secreted either by tumour cells or by host cells, play
an important role as mediators and/or regulators of tumour–host
interactions leading to the progression of malignant tumours
(Kerbel RS, 1992). Indeed, the importance of immunologic para-
meters for diagnosis, prognosis and therapy in clinical oncology is
more evident every day. Several of these immunologic parameters
related with the malignant progression of melanoma have been
reported. Among them, we and other authors have demonstrated
that high levels of soluble Interleukin-2 receptor (sIL-2R) in the
serum of patients with melanoma could be a predictive factor of
metastatic progression (Fierro et al, 1992; Boyano et al, 1997).
Soluble IL-2R is a truncated portion of the alpha chain of the IL-
2R that is expressed in the membrane and is able to bind to IL-2
with the same affinity as the form anchored to the membrane
(Josimovic-Alasevic et al, 1988). The release of sIL-2R is a
phenomenon associated with cellular activation and appears to
play an important role in regulating the immune response
(Fernandez-Botran R, 1991).
The intercellular adhesion molecule-1 (ICAM-1) is a protein
associated with the IL-2R, it is in proximity with the high-
affinity IL-2 receptor and interacts physically with it (Burton
et al, 1990). ICAM-1 is the counter-receptor for leukocyte
function-associated antigen-1 (LFA-1) (Marlin and Springer, 1987;
Staunton et al, 1990). The LFA-1/ICAM-1 interaction is impor-
tant in a number of leukocyte adhesion activities, including the
conjugate formation between cytotoxic T lymphocytes (CTL)
and their targets (Vanky et al, 1990) and natural killer (NK)-
or lymphokine-activated killer (LAK)- mediated cytolysis
(Timonen et al, 1988). Together with ICAM-1 tissue expression,
the existence of soluble forms of this molecule has been demon-
strated in the serum of normal subjects, and serum levels of
soluble ICAM-1 are reportedly correlated with the liver metas-
tasis of a variety of tumours and with disease progression in
melanoma (Johnson et al, 1989; Tsujisaki et al, 1991; Banks et
al, 1993).
Interleukin-10 (IL-10) is a cytokine that contributes to the
down-regulation of the immune response. It was described as a
cytokine inhibiting several different cell functions of the immune
system, including T- and NK-cell and monocyte/macrophage
functions (Fiorentino et al, 1991; Taga and Tosako, 1992). IL-10
mRNA is expressed in human melanoma cell lines (Chen et al,
1994), and elevated serum levels of IL-10 in patients with
metastatic malignant melanoma have been observed (Dummer et
al, 1995). However, IL-10 exhibits antitumoral and antimetastatic
activity in some experimental systems (Huang et al, 1996; Landáyi
et al, 1998).
The aim of the present study is to evaluate the prognostic impact
of the combined detection of sIL-2R, sICAM-1 and IL-10 in the
serum of patients throughout several stages of melanoma. For this
purpose, patients were followed longitudinally through repeated
sIL-2R, sICAM-1 and IL-10 measurements over a three-year
follow-up period.
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Summary Serum soluble interleukin-2 receptor (sIL-2R), intercellular adhesion molecule-1 (sICAM-1) and interleukin-10 (IL-10) have each
been reported as useful markers for melanoma progression. To evaluate the clinical relevance of these three markers, we simultaneously
analysed their serum levels in patients with melanoma. A longitudinal study with a 3-year follow-up was performed and different stages of the
disease were considered. Mean values of sIL-2R were significantly higher than in normal controls in all stages and correlated with the disease
progression. The prognosis of patients with levels > 529 U/ml of sIL-2R was significantly poorer than in patients with sIL-2R levels < 529 U/ml.
Levels of sICAM-1 were also elevated in melanoma patients, specially at the time of the metastatic disease. Serum IL-10 levels were more
frequently detectable in the patients that developed metastasis during follow-up, and the prognosis of patients with detectable IL-10 levels
was significantly poorer than in those patients with IL-10 undetected levels. Statistical analysis based on Logistic and Cox regression models
showed that only sex, stage and sIL-2R value are factors significantly associated with metastatic progression. Moreover, high levels of sIL-2R
could be a risk factor for malignant progression in melanoma. © 2000 Cancer Research Campaign
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Patients
The study focused on 242 patients with histologically confirmed
malignant melanoma (162 women and 80 men, mean age 52 years,
range 19–77). The patients were untreated except for primary
surgery, and were free of infections as judged by clinical evalua-
tion and absence of raised infectious parameters in the blood. After
surgery of the primary tumour, patients go through medical exam-
ination every three months during the first two years and after that,
every six months until five years of follow-up. After the fifth year,
they attend an annual revision up to the tenth year. Those patients
who develop metastasis during the follow-up period are newly
examined every three months for the following two years. The
presence or absence of metastasis was assessed in all patients
by physical examination, laboratory and radiological tests. The
appearance of metastasis was always confirmed by radiographic
examination and/or computed tomography scanning. Disease
stages were classified according to the American Joint Committee
on Cancer (AJCC). Patients’ featured are shown in Table 1. The
patients were divided into two groups: patients whose diagnosis
and surgery for primary melanoma occurred during the study’s
period of time and whose first serum samples were tested within
the first month after surgery (group N, named after new patients),
and patients who had undergone surgery for primary melanoma
several years before the beginning of this study (group F, named
after follow-up patients). 24 patients developed metastasis during
follow-up, 13 patients from group N and 11 patients from group F.
After the first serum determination, new serum samples were
tested every 3 or 6 months during follow-up, from June 1994 to
December 1997. The control group consisted of 58 healthy donors
with comparable sex and age distribution characteristics (38
women and 20 men, mean age 47 years, range 22–57).
Patient and control sera, obtained from venous blood samples,
were divided into aliquots and stored at –70°C until use.
Detection of serum sIL-2R, ICAM-1 and IL-10 levels
Serum sIL-2R, sICAM-1 and sIL-10 concentrations were
measured using a sandwich enzyme immunoassay. Commercially
available kits were used according to the manufacturers’ instruc-
tions (sIL-2R kit from Immunotech International, France,
Marseilles, sICAM-1 and sIL-10 kits from Boehringer Mannheim,
Mannheim, Germany). Serum sIL-2R, sICAM-1 and IL-10
concentrations were expressed in U/ml, ng/ml and pg/ml respec-
tively, and the sensitivity of the kits were 50 U/ml, 3.4 ng/ml and
5 pg/ml respectively. Lower levels of these values were regarded
as undetectable.
The normal levels of sIL-2R and sICAM-1 were defined by
their measurement in healthy controls. Values were considered
elevated when they exceeded the mean of controls plus two
standard deviations (mean + 2SD).
Statistical analysis
Differences in sIL-2R and sICAM-1 levels between groups were
tested using parametric methods (Student’s t test for unpaired
samples). Differences in sIL-10 levels between groups were tested
using nonparametric methods (Mann-Whitney U test for the two
groups) and the Chi-square (c2) test. Spearman rank-correlation
was performed to describe the correlation between serum levels of
sIL-2R, sICAM-1 and sIL-10. A P value below 0.05 was consid-
ered statistically significant.
The cumulative survival rates were calculated using the Kaplan-
Meier methods, and the statistical significance of differences was
determined by using the log-rank test (P < 0.05). The Logistic and
the Cox proportional hazards regression models were used in order
to determine predictive factors linked to metastatic progression.
Age, sex, stage, metastatic evolution, disease-free interval, sIL-
2R, sICAM-1 and sIL-10 levels were all evaluated. We defined the
disease-free interval as the period (of months) between surgery for
the primary tumour and the appearance of metastasis. For these
analyses, patients presenting less than a 2-year follow-up were
excluded. Disease-free patients at the end of follow-up period
were considered censored observations.
Statistical analysis was performed using SPSS statistical soft-
ware.
RESULTS
Serum levels of sIL-2R, sICAM-1 and sIL-10 in patients
with melanoma
sIL-2R levels were independent of the age of the healthy controls
(P = 0.27) and the melanoma patients (P = 0.84) and did not vary
between sexes (P = 0.33 and P = 0.50, respectively). At the first
serum determination, a significant increase of sIL-2R levels was
found in the melanoma group in comparison with the control
subjects (Table 2). Also highly significant differences in sIL-2R
levels were observed between the patients that developed metas-
tasis during follow-up and the healthy controls. The mean ± SD
values of sIL-2R at the time of the first determination in patients of
the groups N and F without metastasis were 496 ± 208 U/ml
and 494 ± 259 U/ml, respectively. These values increased to
559 ± 210 U/ml and 566 ± 198 U/ml respectively during the
metastatic disease.
Levels higher than 529 U/ml (i.e. mean + 2SD of the mean
value of healthy control subjects) were only found in 1 out of 58
controls (1.7%) and 11 out of 96 (11.5%) patients at the time of the
primary melanoma. However, at the appearance of metastasis, a
53.8% of group N patients and 54.5% of group F presented high
levels of sIL-2R.
On the other hand, when serum sIL-2R levels and stage of the
disease were compared, the mean value of IIA+IIB was significantly
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Table 1 Clinical data of patients
No. of patients No. of patients
in group Na Sex in group Fa Sex
Melanomas 109 40M/69W 133 40M/93W
stageb
IA 28 10M/18W 27 8M/19W
IB 28 4M/24W 42 8M/34W
IIA 34 13M/21W 52 18M/34W
IIB 16 10M/6W 10 6M/4W
III 3 3M/0W 2 0M/2W
a Group N, patients whose diagnosis and surgery for primary melanoma
occurred during the period of time of the study and whose serum samples
were tested within the first month after surgery. Group F, patients who had
undergone surgery for primary melanoma several years before first serum
determinations. b Staging system for melanoma is in accordance to the
American Joint Committee.higher than in controls. Three stage III patients presented a non statis-
tically valuable moderate increase of sIL-2R (437 ± 115 U/ml).
Soluble ICAM-1 and IL-10 levels were also quantified in the
N group of melanoma patients. As shown in Table 2, the mean
sICAM-1 levels in controls was 295 ± 80 ng/ml. Significant differ-
ences were detected in relation to age (P < 0.01) but not to sex
(P = 0.34). In melanoma patients, sICAM-1 value was significantly
higher than in controls (342 ± 99 ng/ml) and no sex- or age-related
differences were found (P = 0.36 and P = 0.43, respectively). Also,
higher levels were detected in patients of groups N and F that
developed metastasis during follow-up than in controls.
Levels higher than 455 ng/ml (mean + 2SD) were observed in
17 out of the 109 (15.6%) melanoma patients and none were found
in the controls. Thirteen out of 96 (13.5%) patients with primary
melanomas had high levels of sICAM-1. Also 3 out of 13 (23.1%)
and 3 out of 11 (27.5%) who belonged to the groups N and F
respectively, presented high levels before development of metas-
tasis. When the sICAM-1 determination was performed at the time
of the metastatic disease, the percentages raised to 38.5% and
45.5%, respectively. According to the disease stage, patients with
stages IIA + IIB had significant higher levels than patients with
stages IA + IB. Five out of 56 (12.7%) patients with IA + IB and
15 out of 50 (20%) patients with IIA + IIB stages had sICAM-1
levels higher than 455 ng/ml. Values of sICAM-1 in the three stage
III patients were 328 ± 64 ng/ml.
During follow-up, two or more serum determinations were
analysed each year. In patients who remained disease-free, no
significant differences were found between the sIL-2R and
sICAM-1 levels at 12, 24 and 36 months after the first determina-
tion (data not shown). However, an increase of sIL-2R serum
levels until the time of the metastatic disease was observed in 79%
of patients (Fig. 1). Only a 40% presented high levels of sICAM-1.
Survival analysis showed that the prognosis of melanoma
patients from Total and F groups with high levels of sIL-2R at the
first measure was significantly poorer than that of patients with
sIL-2R < 529 U/ml (P = 0.0143 and P = 0.0080, respectively) Fig.
2A and B). Excluding patients of the group N with less than 2-
years follow-up, there was also a significant correlation between
high levels of sIL-2R and prognosis (P = 0.0154). However, there
was no significant correlation between high levels of sICAM-1
and prognosis (P = 0.6361) (Fig. 2D).
Serum IL-10 levels did not correlate with age and sex, in both
the control (P = 0.541 and P = 0.797, respectively) and melanoma
groups (P = 0.143 and P = 0.364, respectively). 78 out of 109
(62.3%) melanoma patients and 36 out of 56 (64%) healthy
controls showed detectable serum IL-10 concentrations (Table 3).
The proportion of patients with detectable IL-10 levels at the time
of primary tumour was similar to that of the controls (58%). In the
patients that developed metastasis during follow-up, serum IL-10
levels were more frequently detectable (85% in group N and 91%
in group F of patients) at the first serum determination. The
analysis of IL-10 values by the Chi-square (c2) test showed
that the ratio of probabilities to detect IL-10 in the serum of
patients that developed metastasis during follow-up was 2.35
(1.62 < PR < 3.41) (confidence interval of 95%).
The division of patients into two groups according to the serum
IL-10 levels – detectable and non-detectable – revealed that the
prognosis of patients with undetectable IL-10 levels was signifi-
cantly better than those with detectable levels (Log rank = 4.44, 
P = 0.0352) (Fig. 2E). However, at the time of the metastatic
disease, and in the patients that remained disease-free after 
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Table 2 sIL-2R and sICAM-1 serum levels in melanoma patients
Cases sIL-2R (U/ml) sIL-2R > 529 sICAM-1 (ng/ml) sICAM-1 > 455
Mean± SD U/ml (%)a Mean ± SD ng/ml (%)b
Controls 58 323 ± 103 1.7 295 ± 80 0
Melanomas 109 393 ± 228 P < 0.05 11.5 342 ± 99 P < 0.05 15.6
Primary tumour 96 379 ± 228 NS 11 340 ± 99 P < 0.005 13.5
Metastasis group  N 13 496  ± 208 P < 0.005c 23.1c 357 ± 99 P < 0.05c 23.1c
559 ± 210 P < 0.005d 53.8d 413 ± 137 P < 0.005d 38.5d
group F 11 494 ± 259 P < 0.005c 45.5c 390 ± 155 P < 0.005c 27.5 c
566 ± 198 P < 0.005d 54.5d 439 ± 133 P < 0.005d 45.5d
Stage
IA + IB 56 377 ± 244 NS 12.7 328 ± 97 NS 8.9
IIA + IIB 50 418 ± 261 P < 0.01 16 359 ± 103 P < 0.005 30
III 3 437 ± 115 0 328 ± 64 0
a Percentage of patients with levels of sIL-2R > 529 U/ml (mean + 2SD with respect to the mean value of controls). b Percentage of patients with levels of
sICAM-1 > 455 ng/ml (mean + 2SD with respect to the mean value of controls). c First serum sIL-2R and sICAM-1 determinations. d sIL-2R and sICAM-1 values
at the time of the metastasis. Group N, patients whose diagnosis and surgery for primary melanoma occurred during the period of time of the study and whose
serum samples were tested within the first month after surgery. Group F, patients who had undergone surgery for primary melanoma several years before the
first serum determinations. P < 0.05, significant versus controls, NS: not significant.
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Figure 1 Individual serum levels of sIL-2R in melanoma patients that
developed metastasis during follow-up. (A) Group N of patients (n = 10);
(B) Group F of patients (n = 9). m = metastasis; † = death24 months of the first IL-10 measurement, a significant decrease in
the percentage of patients with detectable IL-10 levels was
observed. Comparison of IL-10 serum levels between controls and
melanoma patients performed by the nonparametric Mann-
Whitney U test, demonstrated a decrease of IL-10 levels statisti-
cally significant in melanoma patients.
We also analysed the possible correlation between serum sIL-
2R, sICAM-1 and IL-10 concentrations and found that during
follow-up, 12 months after the first serum level determinations,
circulating sICAM-1 was negatively correlated with IL-10 serum
levels (r = 2 0.204, P = 0.047).
Finally, to determine which factors might be predictive of
metastatic progression in melanoma, we employed the Logistic
and Cox regression models. Only group N of patients met the
requirements for analysis with these methods. The factors consid-
ered were age, sex, stage, disease-free interval and the serum
levels of sIL-2R, sICAM-1 and IL-10. We first used a Logistic
proportional hazards regression model to determine the most
informative combination of independent factors for prognosis. The
results showed that sIL-2R (P = 0.001), sex (male) (P = 0.045) and
stage (P = 0.013) were significantly associated with the metastatic
progression of melanoma. As in our study we have examined the
serum levels at different points in time for the same patients, we
used the Cox regression analysis with time dependent covariates
and observed that sIL-2R levels could be used as a prognostic
marker for the metastatic progression of melanoma (P = 0.002)
(Table 4).
DISCUSSION
This paper describes serial measurements of soluble sIL-2R,
sICAM-1 and IL-10 in the serum of patients with melanoma
during a three-year follow-up period. In accordance with a
previous study, we observed that serum sIL-2R levels are elevated
in patients with melanoma in comparison to healthy controls. This
increase was significantly higher in the group of patients that
850 MD Boyano et al
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Figure 2 Disease-free survival curves for melanoma patients in relation to
their serum levels of sIL-2R, sICAM-1 and IL-10. (A) Total group of patients
(n = 242), subdivided according to sIL-2R serum levels; (B) Group F of
patients (n = 133) subdivided according to sIL-2R serum levels; (C, D and E)
Group N of patients subdivided according to sIL-2R, sICAM-1 and IL-10
serum levels, respectively. Patients with less than 24 months follow-up were
excluded. Statistical significance (P < 0.05)
Table 3 sIL-10 serum levels in melanoma patients during the follow-up
First determination After 12 months After 24 months
Cases (%)a IL-10 ng/ml Cases (%)a IL-10 ng/ml Cases (%)a IL-10 ng/ml
Mean ± SD Mean ± SD Mean ± SD
(range) (range) (range)
Controls 56 (64) 7.3 ± 7.5
(0–35)
Melanomas 109 (62.3) 8.2 ± 10 86 (48.8) 6.1 ± 9 47 (25.5) 2.3 ± 4.5*
(0–69) (0–58) (0–17)
Primary tumours 96 (58) 8.3 ± 11.1 74 (45) 5.8 ± 9.7 44 (28) 2.3 ± 4.7*
(0–69) (0–58) (0–17)
Metastasis  group N 13 (85)b 8.0 ± 5.2b 12 (75)b 7.9 ± 6.6b 5 (20)b 1.6 ± 3.6b
(0–21) (0–21) (0–8)
(54)c 7.0 ± 8.7c
(0–27)
group F 11 (91)b 14 ± 7.3b 9(89) 10.8 ± 8.0b 6 (34)b 3.3 ± 5.2b
(0–30) (0–29) (0–11)
(54)c 11.0 ± 14.3c
(0–50)
Stage
IA + IB 56 (63) 7.4 ± 9.1 42 (50) 7.4 ± 11 22 (27) 2.7 ± 5.0*
(0–56) (0–58) (0–17)
IIA + IIB 50 (60) 8.9 ± 12 41 (44) 4.8 ± 7.3 25 (24) 2.0 ± 4.2*
(0–69) (0–32) (0–17)
III 3 6.0 ± 5.3 2 7.5 ± 4.9 0 –
(0–10) (0–11)
a Percentage of melanoma patients with detectable sIL-10. Comparison of serum IL-10 levels between controls and melanoma patients by nonparametric Mann-
Whitney U test (*P < 0.05). Group N, patients whose diagnosis and surgery for primary melanoma occurred during the period of time of the study and whose
serum samples were tested within the first month after surgery. Group F, patients who had undergone surgery for primary melanoma several years before the
first serum determinations. b First serum IL-10 determination. c IL-10 value at the time of the metastasis.developed metastasis during follow-up, and the prognoses of
patients with elevated serum levels of sIL-2R were significantly
poorer than in those patients with normal levels.
The increase of the sIL-2R levels in the serum may be the result
of the immune system activation or could be released directly by
the individual tumour since melanoma cells can express the
IL-2/IL-2R complex (Alileche et al, 1993; Plaisance et al, 1993;
García de Galdeano et al, 1996). In both cases, sIL-2R may
compete with the cell-surface IL-2 receptor for binding to IL-2 for
IL-2-dependent immune responses (Rubin and Nelson, 1980).
Therefore, a large amount of sIL-2R might induce immunosup-
pression and correlate with poor prognosis of melanoma patients.
In our study, we found that serum levels of sIL-2R can serve as an
independent prognostic factor predictive of metastasis progres-
sion. Measurements of sIL-2R at the time of the primary tumour
can be a useful tool to identify melanoma patients with a signifi-
cant risk to develop metastasis during follow-up. Also, high sIL-
2R levels indicate a poor prognosis in patients who had undergone
surgery for primary tumour several years before the determination
of sIL-2R.
The sICAM-1 is another molecule that appears to be closely
correlated with the progression of melanoma (Natali et al, 1990;
Harning et al, 1990; Altamonte et al, 1991; Giavazzi et al, 1992;
Kageshita et al, 1993). It has been suggested that sICAM-1 may
represent a mechanism by which tumour cells escape from the
cytotoxicity mediated by immunoeffector cells. Soluble ICAM-1,
by competition with the membrane-bound ICAM-1, interferes
with the physical interaction of NK and LAK cells with melanoma
cells, thus reducing their susceptibility to cytotoxicity (Becker et
al, 1991). In our study, serum levels of sICAM-1 in the patients
analysed were significantly higher than those of controls. This
increase was more evident in the group of patients that developed
metastasis during follow-up and, even more, at the time of the
metastatic disease.
Similar results were found when IL-10 serum levels were evalu-
ated. At the first determination, serum IL-10 levels were more
frequently detected (2.35 times) in the group of patients that
developed metastasis during follow-up than in the patients that
remained disease-free. The prognosis of patients with detected IL-
10 levels was poorer than in those with undetectable IL-10 levels,
indicating that detectable levels of IL-10 might contribute to
down-regulated anti-tumour response. However, the proportion of
patients with detectable serum levels of IL-10 during the period of
the metastatic disease was similar to that of the controls.
IL-10 is a pleiotropic cytokine that can exert either immuno-
suppressive or immunostimulatory effects on a variety of cells
types. IL-10 is a potent inhibitor of monocyte/macrophage func-
tion (Fiorentino et al, 1991). By contrast, IL-10 can act on B cells
to enhance their viability, cell proliferation, Ig secretion and class
II MHC expression (Howard et al, 1992). On the other hand,
melanoma cells are able to produce IL-10 (Sato et al, 1996),
suggesting that IL-10 could contribute to immunosuppression by
melanoma (Chen et al, 1994). The results of our study could
lead us to think that after the surgery of the primary melanoma,
detection of IL-10 in the serum of patients might be reflecting a
suppressive status of the immune response. So, high serum levels
of IL-10 together with high levels of sIL-2R and sICAM-1 could
be identifying patients that might develop metastasis during the
follow-up.
Finally, it has been demonstrated that IL-10 is an autocrine
growth factor for human melanoma cells and down-regulates the
expression of cellular ICAM-1 on melanoma cells (Yue et al,
1997). In this study, a significant negative correlation between IL-
10 levels and sICAM-1 levels has been observed during follow-up,
after 12 months of the surgery of primary melanoma.
Analysis of the different factors (sex, age, stage, disease-free
interval, serum sIL-2R, sICAM-1 and IL-10 levels) that might be
correlated with the metastatic progression of melanoma showed
that sIL-2R levels, sex and stage were linked to malignant progres-
sion, and that sIL-2R has a predictive value for the metastatic
progression of melanoma. In contrast to previous studies
(Schadendorf et al, 1996), we could not prove that sICAM-1 and
IL-10 are statistically associated to the metastatic progression of
melanoma. These results may be due to the fact that we did not
evaluate patients in advanced stages of melanoma progression.
In conclusion, if progression of melanoma can be attributed to
the tumour cells escaping from the immune system, elevated
concentrations of sIL-2R, could have an effect as inhibitors of
IL-2 activity. Also, sICAM-1’s capacity to inhibit MHC-restricted
specific T-cell melanoma interactions together with the immuno-
suppressive effect of IL-10, could contribute as well to the
metastatic progression of melanoma.
ACKNOWLEDGEMENTS
We thank Dr. T. Palomares for helpful discussion. This work
was supported by grants from the Health Department of the
Government of the Basque Country, NOVARTIS S.A. and the
Bilbao Bizkaia Kutxa (BBK). MDGV was supported by a fellow-
ship of the Basque Government.
REFERENCES
Alileche A, Plaisance S, Han DS, Rubinstein E, Mingari C, Bellomo R, Jasmin C
and Azzarone B (1993) Human melanoma cell line M14 secretes a functional
interleukin 2. Oncogene 8: 1791–1796
Altamonte M, Colizzi F, Esposito G and Maio M (1991) Circulating intercellular
adhesion molecule-1 as a marker of disease progression in cutaneous
melanoma. N Engl J Med 327: 959–962
Banks RE, Gearing AJH, Hemingway IK, Norfolk DR, Perren TJ and Selby PJ
(1993) Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and
vascular cell-adhesion molecule-1 (VCAM-1) in human malignancies. Br
Cancer Res 68: 122–124
sIL-2R, sICAM-1 and IL-10 as prognostic markers in melanoma 851
British Journal of Cancer (2000) 83(7), 847–852 © 2000 Cancer Research Campaign
Table 4 Summary of multivariate analysis of independent prognostic
markers in melanoma patients by the Logistic and Cox proportional hazards
model
Covariates (P value)
Logistic regression analysis
Age 0.1321
Sex 0.0451
Stage 0.0131
sIL-2R 0.0013
sICAM-1 0.5773
sIL-10 0.1813
Cox regression analysis
Time-dependent sIL-2R covariate
[(1 < T_Cov < 12)*sIL-2RI + (12 < T_Cov < 24)* sIL-2
R12 + (24 < T_Cov < 36)*sIL-2R24]a
T_Cov 0.0026
Stage 0.0557
Sex 0.2494
a sIL-2R1 corresponds to the value of the first serum determination and sIL-
2R12 and sIL-2R24 correspond to serum determination after 12 and 24
months follow-up.Becker JC, Dummer R, Hartmann AA, Burg G and Schmidt RE (1991) Shedding of
ICAM-1 from human melanoma cell lines induced by IFN-g and tumour
necrosis factor-a. J Immunol 147: 4398–4401
Boyano MD, García-Vázquez MD, Gardeazabal J, García de Galdeano A, Smith-
Zubiaga I, Cañavate ML, Ratón JA, Bilbao I and Díaz-Pérez JL (1997) Serum-
soluble IL-2 receptor and IL-6 levels in patients with melanoma. Oncology 54:
400–406
Burton J, Goldman CK, Rao P, Moos M and Waldmann TA (1990) Association of
intercellular adhesion molecule 1 with the multichain high-affinity interleukin-
2 receptor. Proc Natl Acad Sci USA 78: 7329–7333
Chen Q, Daniel V, Maher DW and Hersey P (1994) Production of IL-10 by
melanoma cells: examination of its role in immunosuppression mediated by
melanoma. Int J Cancer 56: 755–760
Dummer W, Becker JC, Achwaaf A, Leverkus M, Moll T and Brocker EB (1995)
Elevated serum levels of interleukin-10 in patients with metastatic malignant
melanoma. Melanoma Res 5: 67–68
Fernandez-Botran R (1991) Soluble cytokine receptors: their role in
immuneregulation. FASEB J 5: 2567–2574
Fierro MT, Lisa F, Novelli M, Beretero M and Bernengo MG (1992) Soluble
Interleukin-2 receptor, CD4 and CD8 levels in melanoma: A longitudinal study.
Dermatology 184: 182–189
Fiorentino DF, Zlotnik A, Mosmann TR, Howard M and O’Garra A (1991a) IL-10
inhibits cytokine production by activated macrophages. J Immunol 147:
3815–3822
Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW and
O’Garra A (1991b) IL-10 acts on the antigen-presenting cell to inhibit cytokine
production by Th1 cells. J Immunol 146: 3444–3451
García de Galdeano A, Boyano MD, Smith-Zubiaga I and Cañavate ML (1996)
B16F10 murine melanoma cells express interleukin-2 and a functional
interleukin-2 receptor. Tumor Biol 17: 155–167
Giavazzi R, Chirivi RGS, Garafalo A, Rambaldi A, Hemingway I and Pigott R
(1992) Soluble intercellular adhesion molecule-1 is released by human
melanoma cells and is associated with tumour growth in nude mice. Cancer
Res 52: 2628–2630
Harning R, Mainolfi E, Bystryn JC, Henn M, Merluzzi VJ and Rothlein R (1990)
Serum levels of circulating intercellular adhesion molecule-1 in human
malignant melanoma. Cancer Res 51: 5003–5005
Howard M, O’Garra A, Ishida H, de Waal MR and de Vries J (1992) Biological
properties of Interleukin-2. J Clin Immunol 12: 239–247
Huang S, Xie K, Bucana CD, Ullrich SE and Bar-Eli M (1996) Interleukin 10
suppresses tumour growth and metastasis of human melanoma cells: potential
inhibition of angiogenesis. Clin Cancer Res 2: 1969–1979
Johnson JP, Stade BG, Holtzmann B, Schwable W and Riethmuller G (1989) De
novo expression of intercellular adhesion molecule 1 in melanomas correlates
with increased risk of metastasis. Proc Natl Acad Sci USA 86: 641–644
Josimovic-Alasevic O, Herrmann T and Diamantstein T (1988) Demonstrations of
two distinct forms of released low-affinity type interleukin-2 receptors. Eur J
Immunol 18: 1855–1857
Kageshita T, Yoshii A, Kimura N, Ono t, Tsujisaki M, Imai K and Ferrone S (1993)
Clinical relevance of ICAM-1 expression in primary lesions and serum of
patients with malignant melanoma. Cancer Res 53: 4927–4932.
Kerbel RS (1992) Expression of multi-cytokine resistance and multigrowth factor
independence in advanced stage metastatic cancer. Am J Pathol 141:
519–524
Landáyi A, Nagy JO, Jeney A and Tímar J (1998) Cytokine sensitivity of metastatic
human melanoma cells lines- simultaneous inhibition of proliferation and
enhancement of gelatinase activity. Pathology Oncology Res 2: 108–114
Marlin SD and Springer TA (1987) Intecellular adhesion molecule-1 (ICAM-1) is a
ligand for lymphocyte function-associated antigen-1 (LFA-1). Cell 15:
831–843
Natali P, Nicotra MR, Cavalieri R, Bigotti A, Romano G, Temponi M and Ferrone S
(1990) Differential expression of intercellulat adhesion molecule 1 in primary
and metastatic melanoma lesions. Cancer 50: 1271–1278
Plaisance S, Rubinstein E, Alileche A, Han DS, Sahraoui Y, Mingari C, Bellomo R,
Rimoldi D, Colombo MP and Jasmin C (1993) Human melanoma cells express
a functional interleukin-2 receptor. Int J Cancer 55: 164–170
Rubin LA and Nelson DL (1990) The soluble interleukin-2 receptor: Biology,
function and clinical application. Ann Inter Med 113: 619–627
Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ and Berd D
(1916) Interleukin 10 production by human melanoma. Clin Cancer Res 2:
1383–1390
Schadendorf D, Diehl S, Zuberbier T, Schadendorf C and Henz BM (1996)
Quantitative detection of soluble adhesion molecules in sera of melanoma
patients correlates with clinical stage. Dermatology 192: 89–93
Staunton DE, Daustin ML, Erickson HP and Springer TA (1990) The arrangement of
the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1.
Cell 61: 243–254
Taga K and Tosako G (1992) IL-10 inhibits human T cell proliferation and IL-2
production. J Immunol 148: 1143–1147
Timonen T, Patarroyo M and Gahmberg CG (1988) CD11a-c/CD18 and GP84 (LB-
2) adhesion molecules on human large granular lymphocytes and their
participation in natural killing. J Immunol 141: 1041–1046
Tsujisaki M, Imai K, Hirata H, Hanzawa Y, Masuya J, Nakano T, Sugiyama T,
Matsui M, Hinoda Y and Yachi A (1991) Detection of circulating
intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp
Immunol 85: 3–8
Vanky F, Wang P, Patarroyo M and Klein E (1990) Expression of the adhesion
molecule ICAM-1 and major histocompatibility complex class I antigens on
human tumour cells is required for their interaction with autologous
lymphocytes in vitro. Cancer Immunol Immunother 31: 19–27
Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S and Burg G
(1997) Interleukin-10 is a growth factor for human melanoma cells and down-
regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 71:
630–637
852 MD Boyano et al
British Journal of Cancer (2000) 83(7), 847–852 © 2000 Cancer Research Campaign